Scholarlink

Background <p><i>Salmonella</i> gastrointestinal infections are common in low- and middle-income countries; however, there is limited data on the clinical presentation and microbiological characteristics of invasive <i>Salmonella</i> disease in Latin America.</p> Methods <p>A cross-sectional study was conducted, including all patients with <i>Salmonella</i> spp. isolated from usually sterile sites at our center from May 2016 to June 2025. Data on demographics, comorbidities, immunological status, symptoms, treatment, and outcomes were collected from medical records. The isolated serogroups and their antimicrobial resistance patterns were analyzed using historical data from the Bacteriology Laboratory electronic database. Descriptive statistical methods were used for data analysis.</p> Results <p>A total of 77 cases of invasive <i>Salmonella</i> infection were identified. Most patients were male (76.6%), with a median age of 33 years. HIV infection was present in 80.5% of cases, and 88.7% of these individuals had advanced disease. Fever was the most frequent symptom (85.7%), and 10.4% required admission to the intensive care unit. Overall mortality was 13%, and all fatal cases occurred among people living with HIV (PWH). The most common treatment was third-generation cephalosporins (58.4%). Resistance to aminoglycosides was documented in all isolates; 52.3% were resistant to trimethoprim-sulfamethoxazole and 6% to ceftriaxone. Ciprofloxacin non-susceptibility reached 64.8%. Multidrug resistance was observed in 12.6% of isolates.</p> Conclusions <p>Invasive <i>Salmonella</i> disease primarily affected immunocompromised individuals, particularly PWH, with fever and bacteremia being the predominant clinical manifestations. Although multidrug resistance was relatively low, the high prevalence of ciprofloxacin non-susceptibility highlights the need to revise regional empirical treatment strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical and microbiological profile of invasive Salmonella disease in Mexico: a single-center retrospective study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月27日

查看全文
  • Edwin Jeffry Palma-Díaz,
  • Juan Carlos Domínguez-Hermosillo,
  • Javier Tondopó-Guerrero,
  • Alberto Chaparro-Sánchez,
  • José Antonio Mata-Marín,
  • Eva Aurora Hernández-Sánchez,
  • Pamela Soto-Santillán,
  • Jesús Enrique Gaytán-Martínez

摘要

Background

Salmonella gastrointestinal infections are common in low- and middle-income countries; however, there is limited data on the clinical presentation and microbiological characteristics of invasive Salmonella disease in Latin America.

Methods

A cross-sectional study was conducted, including all patients with Salmonella spp. isolated from usually sterile sites at our center from May 2016 to June 2025. Data on demographics, comorbidities, immunological status, symptoms, treatment, and outcomes were collected from medical records. The isolated serogroups and their antimicrobial resistance patterns were analyzed using historical data from the Bacteriology Laboratory electronic database. Descriptive statistical methods were used for data analysis.

Results

A total of 77 cases of invasive Salmonella infection were identified. Most patients were male (76.6%), with a median age of 33 years. HIV infection was present in 80.5% of cases, and 88.7% of these individuals had advanced disease. Fever was the most frequent symptom (85.7%), and 10.4% required admission to the intensive care unit. Overall mortality was 13%, and all fatal cases occurred among people living with HIV (PWH). The most common treatment was third-generation cephalosporins (58.4%). Resistance to aminoglycosides was documented in all isolates; 52.3% were resistant to trimethoprim-sulfamethoxazole and 6% to ceftriaxone. Ciprofloxacin non-susceptibility reached 64.8%. Multidrug resistance was observed in 12.6% of isolates.

Conclusions

Invasive Salmonella disease primarily affected immunocompromised individuals, particularly PWH, with fever and bacteremia being the predominant clinical manifestations. Although multidrug resistance was relatively low, the high prevalence of ciprofloxacin non-susceptibility highlights the need to revise regional empirical treatment strategies.